Alyeska Investment Group’s CorMedix CRMD Stock Holding History

Alyeska Investment Group’s Portfolio CRMD Stock Details CRMD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$6.67M	Hold	850,000	–	–	0.02%	474
2026 Q1	$5.77M	Hold	850,000	–	–	0.02%	458
2025 Q4	$9.89M	Sell	850,000 -412,979	-33%	-$4.57M	0.03%	392
2025 Q3	$14.7M	Buy	1,262,979 +512,979	+68%	+$6.2M	0.04%	330
2025 Q2	$9.24M	Buy	+750,000	New	+$8.28M	0.03%	368
2023 Q4	–	Sell	-150,000	Closed	-$555K	–	545
2023 Q3	$555K	Sell	150,000 -850,000	-85%	-$3.38M	﹤0.01%	443
2023 Q2	$3.96M	Buy	+1,000,000	New	+$4.95M	0.03%	356

Other funds holding CRMD

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Royce & Associates New York $12.4B AUM 64.17% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

OAM

Oberweis Asset Management Lisle, Illinois $4.84B AUM 160.95% 1-Year Est. Return

Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Alyeska Investment Group's CRMD Position: Q2 2026 in Review

Alyeska Investment Group held its CorMedix (CRMD) position steady in Q2 2026 at 850,000 shares worth $6.67M. The position accounts for 0.02% of the portfolio, ranked #474.

Alyeska Investment Group first reported a position in CRMD in Q2 2023 and has held it in 7 quarters since. The position peaked at $14.7M in Q3 2025. 194 funds tracked by Wall St. Rank hold CRMD as of Q2 2026.

Alyeska Investment Group held 850,000 shares of CorMedix worth $6.67M as of Q2 2026.
Alyeska Investment Group left its CorMedix share count unchanged in Q2 2026.
CorMedix made up 0.02% of Alyeska Investment Group's portfolio in Q2 2026, its #474 holding.
Alyeska Investment Group first reported a position in CorMedix in Q2 2023 and has held it in 7 quarters since.
Alyeska Investment Group's CorMedix position peaked at $14.7M in Q3 2025.
194 funds tracked by Wall St. Rank held CorMedix as of Q2 2026.

Based on Alyeska Investment Group's 13F filing for Q2 2026, filed 14 Aug 2026.